PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29479969-0 2018 Detection of Cytochrome P450 Polymorphisms in BreastCancer Patients May Impact on Tamoxifen Therapy Background: Breast cancer is the most common cancer among women worldwide. Tamoxifen 82-91 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 13-28 29436156-3 2018 We tested for associations between CYP diplotypes and plasma concentrations of tamoxifen and metabolites. Tamoxifen 79-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 35-38 29436156-0 2018 Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People. Tamoxifen 50-59 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 29479969-2 2018 TAM is metabolized by cytochrome P450 (CYP450) enzymes,including CYP2D6, CYP3A5 and CYP2C19, whose genetic variations may have clinicopathological importance.However, reports on the association of various P450 polymorphisms with certain cancers are contradictory. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 22-37 29479969-2 2018 TAM is metabolized by cytochrome P450 (CYP450) enzymes,including CYP2D6, CYP3A5 and CYP2C19, whose genetic variations may have clinicopathological importance.However, reports on the association of various P450 polymorphisms with certain cancers are contradictory. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 39-45 26446141-1 2016 BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6. Tamoxifen 45-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-116 27198207-1 2016 Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP). Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 76-91 27198207-1 2016 Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP). Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 93-96 27198207-2 2016 CYP phenotypes have been correlated to tamoxifen outcomes, but few have considered drug interactions or combinations of genes. Tamoxifen 39-48 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-3 26896706-2 2016 TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 85-100 26896706-2 2016 TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 102-105 26446141-1 2016 BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6. Tamoxifen 45-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 118-121 24265353-3 2014 Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 28-43 26423799-3 2015 In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins. Tamoxifen 187-190 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 67-70 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 29-44 25940823-3 2015 Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 46-49 25114852-1 2014 Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform. Tamoxifen 21-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 84-99 25114852-1 2014 Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform. Tamoxifen 21-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-104 24265353-3 2014 Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-51 24265353-4 2014 Several genetic variants in the CYP450 enzymes reduce tamoxifen metabolism, leading to reduced endoxifen levels. Tamoxifen 54-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 32-38 24265353-8 2014 Genotyping of 33 single nucleotide polymorphisms in CYP450 genes involved in tamoxifen metabolism was carried out using Sequenom MassARRAY. Tamoxifen 77-86 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 52-58 21750172-1 2011 BACKGROUND: Tamoxifen is oxidized by cytochrome-P450 enzymes (e.g., CYP2D6) to two active metabolites, which are eliminated via glucuronidation by UDP-glucuronosyl transferases (UGT). Tamoxifen 12-21 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 37-52 22617226-0 2012 Effects of CYP induction by rifampicin on tamoxifen exposure. Tamoxifen 42-51 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 11-14 22617226-3 2012 We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P <= 0.040) concentrations of tamoxifen and its metabolites. Tamoxifen 100-109 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 28-43 22617226-3 2012 We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P <= 0.040) concentrations of tamoxifen and its metabolites. Tamoxifen 100-109 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-48 22617226-3 2012 We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P <= 0.040) concentrations of tamoxifen and its metabolites. Tamoxifen 250-259 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-48 22617226-5 2012 Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers. Tamoxifen 49-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 76-79 22041137-2 2012 Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 43-58 22041137-2 2012 Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 60-63 22041137-4 2012 The genetic polymorphisms in the other drug-metabolizing enzymes, including other CYP isoforms, sulfotransferases and UDP-glucuronosyltransferases might contribute to individual differences in the tamoxifen metabolism and clinical outcome of tamoxifen therapy although their contributions would be small. Tamoxifen 197-206 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 82-85 22041137-4 2012 The genetic polymorphisms in the other drug-metabolizing enzymes, including other CYP isoforms, sulfotransferases and UDP-glucuronosyltransferases might contribute to individual differences in the tamoxifen metabolism and clinical outcome of tamoxifen therapy although their contributions would be small. Tamoxifen 242-251 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 82-85 21226615-2 2011 The conversion of tamoxifen to active metabolites involves several cytochrome P450 (CYP) enzymes. Tamoxifen 18-27 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 67-82 21226615-2 2011 The conversion of tamoxifen to active metabolites involves several cytochrome P450 (CYP) enzymes. Tamoxifen 18-27 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 84-87 15159443-0 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. Tamoxifen 28-37 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 80-95 20052538-2 2010 Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen. Tamoxifen 20-29 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 61-76 20052538-2 2010 Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen. Tamoxifen 20-29 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 78-81 19574470-2 2009 CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen. Tamoxifen 9-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 52-67 19574470-2 2009 CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen. Tamoxifen 9-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 69-72 18001838-4 2007 We present a review of the major polymorphic CYP alleles and conclude that this variability is of greatest importance for treatment with several antidepressants, antipsychotics, antiulcer drugs, anti-HIV drugs, anticoagulants, antidiabetics and the anticancer drug tamoxifen. Tamoxifen 265-274 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-48 17434921-2 2007 Tamoxifen is metabolized by various cytochrome P450 (CYP) enzymes, but predominantly by CYP3A4. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 36-51 17434921-2 2007 Tamoxifen is metabolized by various cytochrome P450 (CYP) enzymes, but predominantly by CYP3A4. Tamoxifen 0-9 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 53-56 15596297-2 2005 TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 22-37 15596297-2 2005 TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5. Tamoxifen 0-3 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 39-45 20877451-5 2010 Cytochrome P450 (CYP) enzymes, CYP2D6 in particular, play a major role in the metabolism of tamoxifen to active metabolites. Tamoxifen 92-101 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 20877451-5 2010 Cytochrome P450 (CYP) enzymes, CYP2D6 in particular, play a major role in the metabolism of tamoxifen to active metabolites. Tamoxifen 92-101 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 17-20 20425602-2 2010 Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform. Tamoxifen 21-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 84-99 20425602-2 2010 Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform. Tamoxifen 21-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-104 14652237-1 2003 BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. Tamoxifen 12-21 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-154 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 104-113 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 206-209 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 104-113 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 189-204 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 104-113 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 206-209 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 59-68 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 189-204 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 59-68 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 206-209 15111773-4 2004 A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. Tamoxifen 104-113 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 189-204 14652237-1 2003 BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. Tamoxifen 12-21 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 156-159 14652237-6 2003 To determine which CYP isoforms were involved in the metabolism of tamoxifen to specific metabolites, we used CYP isoform-specific inhibitors. Tamoxifen 67-76 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 19-22 14652237-6 2003 To determine which CYP isoforms were involved in the metabolism of tamoxifen to specific metabolites, we used CYP isoform-specific inhibitors. Tamoxifen 67-76 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 110-113 4004771-1 1985 It is well established that liver microsomal cytochrome P-450 participates in steroid metabolism and probably also in the metabolism of anti-oestrogens such as tamoxifen (Nolvadex). Tamoxifen 160-169 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-61 14678248-0 2003 Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Tamoxifen 24-33 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 62-77 9498238-0 1998 Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Tamoxifen 81-90 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-29 9498238-7 1998 These data suggest that the human endometrial epithelium has the potential of producing CYP enzymes known to generate genotoxic intermediates from tamoxifen and metabolites that affect oestrogen receptors. Tamoxifen 147-156 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 88-91 12124303-0 2002 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4"-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Tamoxifen 14-23 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-60 12124303-1 2002 The cytochrome P450 (P450)-mediated biotransformation of tamoxifen is important in determining both the clearance of the drug and its conversion to the active metabolite, trans-4-hydroxytamoxifen. Tamoxifen 57-66 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 4-19 4061517-1 1985 Variations in cytochrome P-450 levels may influence the responsiveness of uterine and breast tissue as well as carcinomas to endocrine therapy and may be of particular importance with agents such as tamoxifen (Nolvadex) where hydroxylation is known to alter therapeutic activities. Tamoxifen 199-208 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 4061517-1 1985 Variations in cytochrome P-450 levels may influence the responsiveness of uterine and breast tissue as well as carcinomas to endocrine therapy and may be of particular importance with agents such as tamoxifen (Nolvadex) where hydroxylation is known to alter therapeutic activities. Tamoxifen 210-218 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 4004771-1 1985 It is well established that liver microsomal cytochrome P-450 participates in steroid metabolism and probably also in the metabolism of anti-oestrogens such as tamoxifen (Nolvadex). Tamoxifen 171-179 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-61